BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32243362)

  • 1. Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy.
    Mao J; Du P; Yang HT; Hu H; Wang SY; Wu X; Cheng ZB
    Medicine (Baltimore); 2020 Apr; 99(14):e19420. PubMed ID: 32243362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
    Buchler T; Pavlik T; Melichar B; Bortlicek Z; Usiakova Z; Dusek L; Kiss I; Kohoutek M; Benesova V; Vyzula R; Abrahamova J; Obermannova R
    BMC Cancer; 2014 May; 14():323. PubMed ID: 24884897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
    Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
    Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.
    Yang XQ; Li Y; Chen C; Peng CW; Liu SP; Liu Y
    Med Oncol; 2011 Sep; 28(3):789-95. PubMed ID: 20373053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Carcinoembryonic Antigen (CEA), AFP, CA19-9 and CA125 for Patients with Colorectal Cancer with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy.
    Huo YR; Huang Y; Liauw W; Zhao J; Morris DL
    Anticancer Res; 2016 Mar; 36(3):1041-9. PubMed ID: 26976996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
    Spencer SK; Pommier AJ; Morgan SR; Barry ST; Robertson JD; Hoff PM; Jürgensmeier JM
    Br J Cancer; 2013 Nov; 109(11):2765-73. PubMed ID: 24149180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Zhang Y; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
    Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
    Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer.
    Tsai HL; Chang YT; Chu KS; Chen CF; Yeh YS; Ma CJ; Wu DC; Kuo CH; Chan HM; Sheen MC; Wang JY
    Int J Biol Markers; 2008; 23(4):244-8. PubMed ID: 19199273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242.
    Björkman K; Mustonen H; Kaprio T; Kekki H; Pettersson K; Haglund C; Böckelman C
    Tumour Biol; 2021; 43(1):57-70. PubMed ID: 33935125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
    Dirican A; Kucukzeybek Y; Alacacioglu A; Varol U; Aksun S; Bayoglu IV; Demir L; Coban E; Sutcu R; Tarhan MO
    Med Oncol; 2014 Apr; 31(4):905. PubMed ID: 24596030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
    J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
    Huh JW; Lee WY; Park YA; Cho YB; Yun SH; Kim HC; Chun HK
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):435-41. PubMed ID: 24414039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.